| CAS: | 123524-52-7 |
| MF: | C33H34N4O6 |
| MW: | 582.65 |
| EINECS: | 634-143-0 |
| Product Categories: | Inhibitors;Cardiovascular Drugs;API |
| Mol File: | 123524-52-7.mol |
 |
|
| Azelnidipine Chemical Properties |
| Melting point | 120-126°C |
| Boiling point | 709.3±60.0 °C(Predicted) |
| density | 1.33±0.1 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Inert atmosphere,Room temperature |
| solubility | DMSO: >10mg/mL |
| form | powder |
| pka | 7.89(at 25℃) |
| color | Yellow |
| Merck | 14,907 |
| InChIKey | ZKFQEACEUNWPMT-UHFFFAOYSA-N |
| CAS DataBase Reference | 123524-52-7(CAS DataBase Reference) |
| Azelnidipine Usage And Synthesis |
| Description | Azelnidipine, a member of the 1,4-dihydropyridine class of L-type calcium channel blockers with a slow onset profile, was marketed in Japan for the treatment of hypertension. Azelnidipine is synthesized via the condensation of iso-propyl 2-(3- nitrobenzylidene)acetoacetate with (1-diphenylmethylazetidin-3-yl)-3,3-diamino acrylate. The diamino acrylate intermediate is prepared from the cyanoacetic ester by sequential treatment with HCl and ammonia. In receptor binding studies using porcine heart membrane fractions, azelnidipine exhibits an IC50 of 3.1 nM and an apparent Ki of 2.1 nM. Its tight binding and slow onset are correlated with its high lipophilicity. A slow onset is also noted in vitro in a rat aortic strip contraction assay, and this effect continues after removal of the drug from the bath solution. In the conscious spontaneously hypertensive rat (SHR) model of hypertension, it was more potent that nicardipine and also had a more gradual onset and long-lasting effect. This effect was noted both when dosed orally or intravenously. When SHR dosed at 1 or 3 mpk/day for 15 weeks, a sustained reduction in systolic blood pressure was noted (19 and 43 mmHg reduction, respectively). Cardiac output was increased and total peripheral resistance was decreased in each group. Clinical studies of patients with mild-to-moderate hypertension have shown that long-term treatment with azelnidipine provided a sustained decrease in blood pressure (mean reduction systolic /diastolic: 27.8/16.6 mmHg). It similarly controlled blood pressure, as did amlodipine at 24 h. It possesses a gradual onset of activity with plasma levels increasing before the antihypotensive effect is attained. After plasma levels drop, the pharmacodynamic effect is sustained. In clinical studies, azelnidipine did not show reflex tachycardia, a common side effect of this class. Most common side effects were facial flushing and headache, similar to other dihydropyridines. Azelnidipine is dosed orally once daily (8–16 mg), is rapidly absorbed in a dose-dependent fashion, and has a mean terminal half-life of 19.2 h (8 mg dosage p.o. for seven days). Uniquely, it possesses a 2-amino function associated with a longer half-life than related agents wherein this moiety is a methyl. The very highly lipophilic 3-carboxylic ester side-chain is purported to contribute to the gradual onset of activity and prolonged pharmacodynamic effect, unlike other drugs in this class. This compound exhibits a much less pronounced first-pass metabolic effect than nicardipine. |
| Chemical Properties | Yellow Solid |
| Originator | Sankyo (Japan) |
| Uses | Azelnidipine is a dihydropyridine calcium channel blocker with antihypertensice activity. Azelnidipine is used for treating ischemic heart disease and cardiac remodeling after myocardial infarction. S tudies show that Azelnidipine ttreatment can reduce the risk of hyperglycemia induced metabolic disorders |
| Application | Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis. |
| Definition | ChEBI: Azelnidipine is an isopropyl ester. |
| Brand name | Calblock |
| Biological Activity | Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis. |
Packing &shipping&Payment
Packing:25kg/drum
Shipping:by sea or by air
Payment:T/T,western union,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :
| Quantity(Kilograms) | 1 - 10000 | >10000 |
| Est. Time(days) | 5 | To be negotiated |
Company information
Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in 4'-Methylacetophenone,Levamisole hydrochloride ,N-Methylformamide and other chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.
Advantage
In stock
Japan
